Key result
Inactivation of the microRNA-degrading enzyme translin/trax reverses the age-dependent decline in miR-181b and confers protection from aging-associated arterial stiffening in animal models.
Why the study?
Large artery stiffness is an independent risk factor for cardiovascular disease that increases with aging, stimulating interest in defining microRNA signaling and molecular targets involved in age-associated arterial stiffening.
Design
Review
Authors
Loading...
Translin/trax inactivation may protect against age-related arterial stiffening; leaves open whether targeting this pathway alters clinical cardiovascular outcomes.
This review highlights the therapeutic potential of targeting the translin/trax microRNA-degrading enzyme to restore miR-181b levels and combat aging-associated large-artery stiffness.
Baraban et al. (2021) conducted a review in Large-Artery Stiffness (LAS) associated with aging. miR-181b modulation and translin/trax inhibition was evaluated. Inactivation of the microRNA-degrading enzyme translin/trax reverses the age-dependent decline in miR-181b and confers protection from aging-associated arterial stiffening in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: